Vasomune Therapeutics Inc
180 John St
Toronto, ON M9N 1J8
Vasomune Therapeutics Inc. is a private biotechnology company based in Toronto, Ontario, focused on the development of AV-001, a first-in-class fully synthetic PEGylated peptide that targets the Tie2 receptor. This innovative therapeutic aims to enhance vascular stability, bolster barrier integrity, and promote endothelial quiescence through the activation of the Tie2 receptor.
In addition to its headquarters in Toronto, Vasomune Therapeutics also operates a branch in Raleigh, North Carolina. The company is committed to advancing its groundbreaking research to improve health outcomes in vascular-related conditions.
Generated from the website
Also at this address
See a problem?
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.